Patents Assigned to Novo Alle
-
Publication number: 20140161802Abstract: The current invention relates to the treatment of diseases characterized by cartilage destruction and/or bone erosion. In particular the present invention relates to the treatment of osteoarthritis, osteoporosis, psoriatic arthritis or rheumatic arthritis with an anti-NKG2A antibody.Type: ApplicationFiled: June 18, 2012Publication date: June 12, 2014Applicant: NOVO ALLEInventors: Kalle Soederstroem, Elisabeth Douglas Galsgaard
-
Publication number: 20130143269Abstract: The present invention relates to agents and methods that are capable of augmenting NK-mediated killing of target cells by reducing inhibitory KIR signalling without reducing the binding of KIR to HLA-C. As described herein, transduction of negative signaling via KIR, upon binding of KIR to its HLA class I ligand, can involve a ligand-binding induced, conformational reorientation of the KIR molecules allowing interactions to form between adjacent KIRs in specific domains, leading to accelerated clustering. Methods and agents such as monoclonal antibodies for reducing KIR-mediated inhibition of NK cell cytotoxicity without reducing or blocking HLA-binding by, e.g., reducing or blocking dimerization of KIR, are provided.Type: ApplicationFiled: January 18, 2013Publication date: June 6, 2013Applicants: INNATE PHARMA S.A.S, NOVO-NORDISK A/S - NOVO ALLÉInventors: Novo-Nordisk A/S - Novo Allé, Innate Pharma S.A.S
-
Publication number: 20120208237Abstract: Compositions and methods for regulating an immune response in a subject are described. More particularly, described are human antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects, and antibodies having antigen-binding properties similar to those of human monoclonal antibody 1-7F9 or 1-4F1. Described also are also fragments and derivatives of such antibodies, as well as pharmaceutical compositions comprising the same and their uses, particularly for use in therapy, to increase NK cell activity or cytotoxicity in subjects.Type: ApplicationFiled: January 11, 2012Publication date: August 16, 2012Applicants: Innate Pharma S.A.S, Novo-Nordisk A/S - Novo AlleInventors: Alessandro Moretta, Mariella Della Chiesa, Pascale Andre, Laurent Gauthier, Francois Romagné, Peter Andreas Nicolai Reumert Wagtmann, Ivan Svendsen, Stefan Zahn, Anders Svensson, Matthias Thórólfsson, Søren Berg Padkær, Kristian Kjaergaard, Pieter Spee, Michael Wilken
-
Patent number: 6291209Abstract: The present invention relates to a filamentous fungus useful for the production of heterologous polypeptides, having been modified by recombinant DNA technology in a manner by which the expression of alkaline proteases have been completely or partially inactivated. The invention also encompasses processes for the production of proteins of interest in high yields by using the fungi of the invention. The invention furthermore relates to methods for producing such fungi and DNA constructs to be used in these methods.Type: GrantFiled: September 4, 1998Date of Patent: September 18, 2001Assignee: Novo Nordisk A/S Novo alléInventor: Jan Lehmbeck
-
Patent number: 6200792Abstract: The present invention relates to an enzyme exhibiting aminopeptidase activity, a method for producing said enzyme, an enzyme preparation containing said enzyme exhibiting aminopeptidase activity, and use of said enzyme for various industrial purposes.Type: GrantFiled: May 30, 2000Date of Patent: March 13, 2001Assignee: Novo Nordisk-A/S Novo AlleInventors: Markus Sakari Kauppinen, Joan Qi Si, Tina Spendler, Claus Dambmann, Torben Halkier, Peter Rahbek Østergaard, Shamkant Anant Patkar, Kim Hansen
-
Patent number: 6197565Abstract: The invention relates to a variant of a parent Termamyl-like &agr;-amylase, comprising mutations in two, three, four, five or six regions/positions. The variants have increased stability at high temperatures (relative to the parent). The invention also relates to a DNA construct comprising a DNA sequence encoding an &agr;-amylase variant of the invention, a recombinant expression vector which carries a DNA construct of the invention, a cell which is transformed with a DNA construct of the invention, the use of an &agr;-amylase variant of the invention for washing and/or dishwashing, textile desizing, starch liquefaction, a detergent additive comprising an &agr;-amylase variant of the invention, a manual or automatic dishwashing detergent composition comprising an &agr;-amylase variant of the invention, a method for generating a variant of a parent Termamyl-like &agr;-amylase, which variant exhibits increased.Type: GrantFiled: November 16, 1998Date of Patent: March 6, 2001Assignees: Novo-Nordisk A/S, Novo AlleInventors: Allan Svendsen, Sóeren Kjaerulff, Henrik Bisgaard-Frantzen, Carsten Andersen
-
Patent number: 6197352Abstract: The staling of leavened baked products such as bread is retarded by adding an enzyme with exoamylase activity to the flour or dough used for producing the baked product in question.Type: GrantFiled: January 30, 1992Date of Patent: March 6, 2001Assignees: Novo Nordisk A/S, Novo AlleInventor: Tine Olesen
-
Patent number: 6184010Abstract: The present invention relates to a process for enzymatic hydrolysis of cyclic oligomers of poly(ethylene terephthalate), which process comprises subjecting the cyclic oligomer to the action of one or more lipolytic and/or biopolyester hydrolytic enzyme(s).Type: GrantFiled: July 21, 1998Date of Patent: February 6, 2001Assignees: Novo Nordisk A/S, Novo AlleInventors: Martin Riegels, Rainhard Koch, Lars Saaby Pedersen, Henrik Lund
-
Patent number: 6165718Abstract: A method for in vivo production of a library in cells comprising a multitude of mutated genetic elements, wherein an error-prone polymerase is used in each ancestral cell to replicate all or a part of a genetic element independently of the host chromosomal replication machinery. The genetic element comprisesi) an origin of replication from which replication is initiated,ii) optionally a genetic marker, e.g. a gene conferring resistance towards an antibiotic,iii) a gene encoding the polypeptide of interest.Also methods for the generation of a DNA sequence encoding a desired variant of a polypeptide of interest, and for the determination of such a DNA sequence are described.Type: GrantFiled: July 8, 1998Date of Patent: December 26, 2000Assignee: Novo Nordisk A/S Novo AlleInventors: Torben Vedel Borchert, Stanislas Dusko Ehrlich
-
Patent number: 5994373Abstract: The present invention relates to therapeutically active heterocyclic compounds, to methods for their preparation and to pharmaceutical compositions comprising the compounds. The novel compounds are useful in treating diseases in the central nervous system related to malfunctioning of the nicotinic cholinergic system.Type: GrantFiled: December 19, 1997Date of Patent: November 30, 1999Assignee: Novo Nordisk A/S Novo Alle DK 2880Inventor: Preben Houlberg Olesen
-
Patent number: 5905140Abstract: A method of selectively acylating an insulin, an insulin analogue or a precursor thereof having a free .epsilon.-amino group of a Lys residue contained therein and at least one free .alpha.-amino group which method comprises reacting the .epsilon.-amino group with an activated amide in a polar solvent in the presence of a base.Type: GrantFiled: July 8, 1997Date of Patent: May 18, 1999Assignee: Novo Nordisk A/S, Novo AlleInventor: Louis Brammer Hansen
-
Patent number: 5859045Abstract: The present invention provides novel crystalline (-)-3R,4R-trans-7-methoxy-2,2-dimethyl-3-phenyl-4-{4-?2-(pyrrolidin-1-yl)e thoxy!phenyl}chromane, hydrogen fumarate useful for reducing or preventing bone loss as well as pharmaceutical compositions containing the same. A process for preparing (-)-3R,4R-trans-7-methoxy-2,2-dimethyl-3-phenyl-4-{4-?2-(pyrrolidin-1-yl)e thoxy!phenyl}chromane, hydrogen fumarate is described.Type: GrantFiled: May 7, 1997Date of Patent: January 12, 1999Assignee: Novo Nordisk A/S Novo AlleInventors: Svend Treppendahl, Jensen Snej Klaus, Scott E. McGraw
-
Patent number: 5834495Abstract: The invention provides crystalline 3-(4-hexyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridine (+) L-hydrogentartrate, its preparation and use as a therapeutic agent.Type: GrantFiled: November 26, 1996Date of Patent: November 10, 1998Assignee: Novo Nordisk A/S Novo AlleInventors: Linda Marie Osborne, Lisa Ann Shipley, Svend Treppendahl, Torben G. Petersen
-
Patent number: 5688757Abstract: Certain sugar derivatives have bleach-activating effect both on "hydrophilic" stains (e.g. tea or red wine) and on "hydrophobic" stains (e.g. grass or tomato sauce). The compounds in question are derivatives of pentoses or hexoses, having a long-chain acyl group and one or more short-chain acyl or aroyl groups attached through ester bonds. Optionally, a short-chain alkyl group is attached through a glycosidic bond. These compounds are non-toxic and biodegradable, and can conveniently be prepared by methods known in the art.Type: GrantFiled: January 7, 1994Date of Patent: November 18, 1997Assignees: Novo Nordisk A/S The Procter & Gamble Co., Novo AlleInventors: Ture Damhus, Ole Kirk, Frederick Edward Hardy
-
Patent number: 5219751Abstract: This invention is in the field of glucose isomerization enzymes. More specifically, the invention is directed to a novel xylose isomerase, a process for the preparation of this enzyme, the use of this enzyme in glucose isomerization processes, and glucose isomerization processes. The enzyme is preferably derived from Thermotoga maritima or Thermotoga neapolitana. The enzyme has a temperature optimum above 90.degree. C., pH optimum in the range of from 6 to 7 and a residual activity at 90.degree. C. of more than 40% after 30 minutes and/or residual activity at 98.degree. C. of more than 20% after 30 minutes. The enzyme can also be in immobilized form.Type: GrantFiled: October 19, 1990Date of Patent: June 15, 1993Assignees: Novo Nordisk A/S Novo Alle,, John Hopkins UniversityInventors: Robert L. Starnes, Robert M. Kelly, Stephen H. Brown